Last reviewed · How we verify
NCT04523064: POST-CABGDM
POST-CABGDM: Empagliflozin in Perioperative CABG
Phase 4 trial testing Empagliflozin 25 MG in Diabetes Mellitus, Type 2 in 155 participants. Completed in 30 January 2024.
30 January 2024
Quick facts
| Lead sponsor | University of Sao Paulo General Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 155 |
| Start date | 22 September 2020 |
| Primary completion | 30 January 2024 |
| Estimated completion | 30 January 2024 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Empagliflozin 25 MG — full drug profile →
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
- Coronary Artery Bypass Surgery — all drugs for Coronary Artery Bypass Surgery →
- Acute Kidney Injury — all drugs for Acute Kidney Injury →
Sponsor
University of Sao Paulo General Hospital
Who can join
18 and older, any sex, with Diabetes Mellitus, Type 2 or Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction: Diabetes Mellitus (DM) is a condition known to be associated with coronary artery disease (CAD) and its role as promoter of atherosclerosis is well stablished. The revascularization surgery is commonly indicated to patients with multivessel coronary disease and kidney injury is a prevalent complication in post operation. This work aims to evaluate the impact of a strategy to control Diabetes Mellitus using inhibitors of sodium-glucose cotransporters (ISGLT2) in diabetics patients with assigned myocardial revascularization with cardiopulmonary bypass
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.
González-Albarrán O, Morales C, Pérez-Maraver M, Aparicio-Sánchez JJ, et al · · 2022 · cited 8× · PMID 35704167 · DOI 10.1007/s13300-022-01276-2 -
Unveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach.
Pan SY, Huang TT, Jiang ZH, Lin LC, et al · · 2024 · cited 5× · PMID 38934037 · DOI 10.23876/j.krcp.23.289
Verify or expand the search:
- PubMed search for NCT04523064
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Empagliflozin 25 MG
Trials testing the same drug.
- NCT07053306 — SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia · Phase 1 · recruiting
- NCT07053293 — SGLT2i, Hepatic Glucose Production, and SNS · EARLY_PHASE1 · recruiting
- NCT05715814 — meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis · Phase 3 · recruiting
- NCT06578676 — To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults · Phase 1 · recruiting
- NCT06249932 — Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease · Phase 4 · recruiting
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other University of Sao Paulo General Hospital trials
Trials by the same sponsor.
- NCT07275580 — Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
- NCT07478094 — Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost · not yet recruiting
- NCT07341386 — Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases · Phase 4 · not yet recruiting
- NCT07242092 — Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs · Phase 4 · not yet recruiting
- NCT07484152 — Motor and Non-Motor Effects of Low-Intensity Focused Ultrasound (LIFU) as a Neuromodulation Tool in Essential Tremor · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04523064 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Sao Paulo General Hospital
- Last refreshed: 10 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04523064.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing